Suppressor cell function in multiple sclerosis: Correlation with clinical disease activity

No abstract is available for this paper.

• Publication year

  1979

• Venue

  Annals of Neurology

• Publication date

  1979-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ana.410050406PMID 312620
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Suppressor cell function in man: evidence for altered sensitivity of responder cells with age.

  1979cited by this paper
• Circulating suppressor cells in man as a function of age.

  1978cited by this paper
• Further data on mitochondrial malic enzyme in man.

  1978cited by this paper
• Mitogen responsiveness and suppressor cell function in multiple sclerosis

  1978cited by this paper
• Abnormal T cell subpopulations and circulating immune complexes in the Guillain‐Barré syndrome and multiple sclerosis

  1978cited by this paper
• Suppressor cell function in multiple sclerosis.

  1978cited by this paper
• Imbalances in T cell subpopulations in multiple sclerosis patients.

  1978cited by this paper
• [T and B lymphocytes in multiple sclerosis].

  1977cited by this paper
• Functional analysis of two human T-cell subpopulations: help and suppression of B-cell responses by T cells bearing receptors for IgM or IgG

  1977cited by this paper
• Prevention of autoimmunity in experimental lupus erythematosus by soluble immune response suppressor.

  1977cited by this paper
• Circulating immune complexes and multiple sclerosis.

  1977cited by this paper
• In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin basic protein in primary demyelinating diseases.

  1977cited by this paper
• The effect of levamisole on cell-mediated immunity and suppressor cell function.

  1976cited by this paper
• Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

  1976cited by this paper
• Circulating immune complexes in multiple sclerosis and other neurological diseases.

  1976cited by this paper
• B and T lymphocytes in man

  1976cited by this paper
• Cerebrospinal fluid T and B lymphocyte kinetics related to exacerbations of multiple sclerosis

  1976cited by this paper
• Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors

  1976cited by this paper
• A study of B and T cells in multiple sclerosis

  1975cited by this paper
• Biological expressions of lymphocyte activation. IV. Concanavalin A-activated suppressor cells in mouse mixed lymphocyte reactions.

  1975cited by this paper
• Suppressor cell control of unresponsiveness to experimental allergic encephalomyelitis.

  1975cited by this paper
• Circulating Immune Complexes in the Serum in Systemic Lupus Erythematosus and in Carriers of Hepatitis B Antigen QUANTITATION BY BINDING TO RADIOLABELED Clq

  1974cited by this paper
• Circulating immune complexes in the serum in systemic lupus erythematosus and in carriers of hepatitis B antigen. Quantitation by binding to radiolabeled C1q.

  1974cited by this paper
• EFFECT OF PHYTOHEMAGGLUTININ, BASIC PROTEIN AND MEASLES ANTIGEN ON MYO‐(2‐3H)INOSITOL INCORPORATION INTO PHOSPHATIDYLINOSITOL OF LYMPHOCYTES FROM PATIENTS WITH MULTIPLE SCLEROSIS

  1974cited by this paper
• Cellular hypersensitivity to basic myelin (A1) protein and clinical multiple sclerosis.

  1974cited by this paper
• Letter: Domiciliary physiotherapy.

  1974cited by this paper
• INHIBITORY AND STIMULATORY EFFECTS OF CONCANAVALIN A ON THE RESPONSE OF MOUSE SPLEEN CELL SUSPENSIONS TO ANTIGEN

  1973cited by this paper
• INHIBITORY AND STIMULATORY EFFECTS OF CONCANAVALIN A ON THE RESPONSE OF MOUSE SPLEEN CELL SUSPENSIONS TO ANTIGEN

  1972cited by this paper
• Lymphocyte Transformation in Multiple Sclerosis*

  1970cited by this paper
• Inhibition of target cell proliferation by supernatants from cultures of human peripheral lymphocytes.

  1970cited by this paper
• LYMPHOCYTE TRANSFORMATION IN MULTIPLE SCLEROSIS

  1968cited by this paper
• The power of words.

  1951cited by this paper

• IFN-β therapy rescues dysregulated IFN-stimulated proteins, serum cytokines, and neurotrophic factors in multiple sclerosis: Multiplex analysis of short-term and long-term IFN responses

  2025cites this paper
• Increased Percentage of CD8+CD28− Regulatory T Cells With Fingolimod Therapy in Multiple Sclerosis

  2022influential citation
• Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis

  2021cites this paper
• Vitamin D enhances responses to interferon-β in MS

  2019influential citation
• Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection

  2019cites this paper
• How Type I Interferons Work in Multiple Sclerosis and Other Diseases: Some Unexpected Mechanisms

  2014cites this paper
• Amelioration of experimental allergic encephalomyelitis (eae) by phase 2 enzyme inducer

  2010cites this paper
• Ingested Type I Interferon—State of the Art as Treatment for Autoimmunity Part 2

  2010cites this paper
• The sad plight of multiple sclerosis research (low on fact, high on fiction): critical data to support it being a neurocristopathy

  2010cites this paper
• Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon β-1b

  2010cites this paper
• Suppressor cell activity and beta-cell function in insulin-dependent diabetics.

  2009cites this paper
• Multiple Sclerosis and Demyelinating Diseases

  2007cites this paper
• CD8+ T cell activation correlates with disease activity in clinically isolated syndromes and is regulated by interferon-beta treatment.

  2006cites this paper
• Cerebrospinal fluid analysis in a spontaneous canine model of demyelinating disease

  2006cites this paper
• Association of CD45dimVLA-4+ cells with the NKT cell lineage and their selective expression of IL-13, IP-15, and CCR3 transcripts

  2006cites this paper
• Therapeutic role of beta-interferons in multiple sclerosis.

  2006cites this paper
• Neutrophils That Infiltrate the Central Nervous System Regulate T Cell Responses1

  2005cites this paper
• Long-term experience with interferon beta-1b (Betaferon®) in multiple sclerosis

  2005cites this paper
• The Role of Autoimmunity in Multiple Sclerosis

  2005cites this paper
• Encephalomyelitis and Are Unresponsive to Severity of Experimental Autoimmune Middle-Age Male Mice Have Increased

  2005cites this paper
• Nervous System Regulate T Cell Responses Neutrophils That Infiltrate the Central

  2005cites this paper
• Middle-Age Male Mice Have Increased Severity of Experimental Autoimmune Encephalomyelitis and Are Unresponsive to Testosterone Therapy1

  2005cites this paper
• The influence of disease activity on the number of blood cells of multiple sclerosis patients

  2004cites this paper
• Past infectious events and disease evolution in multiple sclerosis

  2004cites this paper
• The role of prostaglandins in altered leukocyte function in multiple sclerosis

  2004cites this paper
• Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis

  2004cites this paper
• HLA-Dw2 Antigen and Chcal Variables

  2004cites this paper
• Influence of Azathroprine (Imuran) on In Vitro

  2004cites this paper
• Evidence for Cytokine Dysregulation in Multiple Sclerosis: Peripheral Blood Mononuclear Cell Production of Pro-inflammatory and Anti-inflammatory Cytokines During Relapse and Remission

  2003cites this paper
• Chapter 4 Immunology of Multiple Sclerosis

  2003cites this paper
• Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome.

  2003cites this paper
• Role of Cytokines in Multiple Sclerosis and in Mucosal Tolerance

  2002cites this paper
• Low expression of interferon-stimulated genes in active multiple sclerosis is linked to subnormal phosphorylation of STAT1.

  2002cites this paper
• Insights into the immunopathogenesis of multiple sclerosis

  2002cites this paper
• Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity

  2002cites this paper
• THE PATHOGENESIS OF MULTIPLE SCLEROSIS REVISITED

  2002cites this paper
• Ingested Type I Interferon: A Potential Treatment for Autoimmunity

  2002cites this paper
• Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis.

  2001cites this paper
• TCR Peptide Therapy in Human Autoimmune Diseases

  2001cites this paper
• Interferon β‐1b in Multiple Sclerosis

  2000cites this paper
• Unregulated inflammation shortens human functional longevity

  2000cites this paper
• Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis.

  2000cites this paper
• Influence of acute submaximal exercise on T-lymphocyte suppressor cell function in healthy young men

  2000influential citation
• Long-term immunological changes in azathioprine-treated MS patients

  2000cites this paper
• T cell vaccination in secondary progressive multiple sclerosis.

  2000cites this paper
• Autoimmunity Is a Type I Interferon-Deficiency Syndrome Corrected by Ingested Type I IFN via the GALT System

  1999cites this paper
• Immune functions in untreated and treated multiple sclerosis patients

  1999cites this paper
• Cellular and humoral immune responses against autoreactive T cells in multiple sclerosis patients after T cell vaccination.

  1999cites this paper
• Hypothesis: Multiple Sclerosis is a Type I Interferon Deficiency Syndrome

  1998cites this paper
• [Changes in lymphocyte subsets s and treatment with beta interferon in active multiple sclerosis].

  1998cites this paper
• A 21 Point Unifying Hypothesis on the Etiology and Treatment of Multiple Sclerosis

  1998cites this paper
• Immunomodulatory effects of interferon-beta-1b in vivo: induction of the expression of transforming growth factor-beta1 and its receptor type II.

  1998cites this paper
• Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: a population based case-control study from western Norway

  1998cites this paper
• Immunomodulatory effects of interferon-β-1b in vivo: induction of the expression of transforming growth factor-β1 and its receptor type II

  1998cites this paper
• All-trans retinoic acid potentiates the ability of interferon beta-1b to augment suppressor cell function in multiple sclerosis.

  1998cites this paper
• Mechanisms of interferon beta action in multiple sclerosis

  1997cites this paper
• Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies.

  1997cites this paper
• Beta-interferon and multiple sclerosis.

  1997cites this paper
• Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis

  1997cites this paper
• Treatment of multiple sclerosis with interferon beta 1b.

  1997cites this paper
• Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy.

  1997cites this paper
• Role of interferons in demyelinating diseases.

  1997cites this paper
• Mechanisms of action of interferon-β in multiple sclerosis

  1996cites this paper
• Interferon beta in multiple sclerosis.

  1996cites this paper
• Human Adjuvant Disease: Presentation as a Multiple Sclerosis–like Syndrome

  1996cites this paper
• Treatment of Multiple Sclerosis with Type I Interferons

  1996cites this paper
• Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis

  1996cites this paper
• Mechanisms of action of interferon-beta in multiple sclerosis.

  1996cites this paper
• Vaccination with autoreactive T cell clones in multiple sclerosis: overview of immunological and clinical data

  1996cites this paper
• Systemic high-dose recombinant-alpha-2a-interferon therapy modulates lymphokine production in multiple sclerosis.

  1996cites this paper
• Interferon beta induces interleukin‐10 expression: Relevance to multiple sclerosis

  1996cites this paper
• Copolymer-1

  1996cites this paper
• Copolymer-l Review of its Pharmacological Properties and Therapeutic Potential in Multiple Sclerosis

  1996cites this paper
• Immunoneurology

  1996cites this paper
• T cell subsets in multiple sclerosis: a serial study

  1995cites this paper
• Reduced frequency of memory CD8+ T lymphocytes in cerebrospinal fluid and blood of patients with multiple sclerosis.

  1995cites this paper
• Clonal expansion of myelin basic protein‐reactive T cells in patients with multiple sclerosis: Restricted T cell receptor V gene rearrangements and CDR3 sequence

  1995cites this paper
• Evidence for a missed signal to the CD8+ cells in CSF of Multiple Sclerosis patients

  1995cites this paper
• Interferon alpha treatment of relapsing–remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function

  1995cites this paper
• Biologic effects of interferons: relevance to multiple sclerosis

  1995cites this paper
• Multiple sclerosis: Immune mechanism and update on current therapies

  1995cites this paper
• Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis.

  1995cites this paper
• Investigations into the cognitive functioning of subjects with epilepsy in relation to anticonvulsant medication

  1995cites this paper
• Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b

  1995cites this paper
• Activation and clonal expansion of human myelin basic protein-reactive T cells by bacterial superantigens.

  1995cites this paper
• Is multiple sclerosis an autoimmune disease?

  1994cites this paper
• A brief history of the use of interferons as treatment of multiple sclerosis.

  1994cites this paper
• Multiple Sclerosis: Pathogenesis and Treatment

  1994cites this paper
• [Increase of interleukin-2 soluble receptors in multiple sclerosis: preliminary study in 26 patients].

  1994cites this paper
• Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: First steps towards monitoring process activity

  1994cites this paper
• Lymphocyte subsets in relapsing-remitting multiple sclerosis: a longitudinal study of B lymphocytes and T lymphocytes.

  1994cites this paper
• Chronic systemic high‐dose recombinant interferon alfa‐2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing‐remitting multiple sclerosis

  1994cites this paper
• High-dose methylprednisolone treatment-induced changes in immunological parameters in progressive MS patients.

  1994cites this paper
• Functional defects in peripheral blood T cells of multiple sclerosis patients. Diminished in vitro responsiveness in accessory cell dependent activation systems.

  1994cites this paper
• Immunotherapy for Multiple Sclerosis

  1994cites this paper
• T suppressor hybridomas and interleukin‐2‐dependent lines induced by copolymer 1 or by spinal cord homogenate down‐regulate experimental allergic encephalomyelitis

  1993cites this paper
• Adhesion molecule expression on cerebrospinal fluid T lymphocytes: Evidence for common recruitment mechanisms in multiple sclerosis, aseptic meningitis, and normal controls

  1993cites this paper
• Anti-lymphocyte antibodies and circulating immune complexes in the sera of patients with myelopathy associated with human T lymphotropic virus type-I.

  1993cites this paper
• Cimetidine as an immunomodulator in subacute sclerosing panencephalitis: a double blind, placebo‐controlled study

  1993cites this paper
• Thymectomy as treatment of autoimmune diseases other than myasthenia gravis.

  1993cites this paper